Current approaches to optimize treatment of dementia and Alzheimer's disease

Kolykhalov I.V.

doi:https://doi.org/10.17116/jnevro20161166187-92

Close metadata

Recommended articles:

Non-invasive biomarkers for early diagnosis of Alzheimer’s disease in bodily fluids. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):8-16

Nutritional care for patients with neurodegenerative diseases in the outpatient practice of a neurologist. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):76-83

The experience of diagnosing Alzheimer’s disease based on the study of cerebrospinal fluid biomarkers. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):91-97

The association of NOS1AP gene polymorphisms with the duration of the QT interval in patients with schizophrenia receiving antipsychotic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):98-104

Neurobiological potential of astragaloside IV and prospects for its use in the treatment of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):7-12

Cytokine status of patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):5-12

The main mechanisms of development of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18

Curcumin-induced increased retinal fluorescence as a new method in the early diagnosis of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):19-25

Differential diagnosis of Alzheimer’s disease and vascular cognitive disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):26-35

Characteristics, treatment features and in-hospital mortality of patients with myocardial infarction over 75 years old in Russia according to the REGION-IM registry. Russian Cardiology Bulletin. 2025;(1):22-38

Abstract:

Currently, substitution therapy is the main focus in the treatment of Alzheimer's disease (AD). It is aimed at overcoming neurotransmitter deficits in a variety of neuronal systems affected in AD. To overcome the cholinergic insufficiency, acetylcholinesterase inhibitors (rivastigmine, donepezil and galantamine) are primarily used. The efficacy and safety of these drugs in AD have been convincingly shown in numerous clinical trials in different countries. Memantine is the main drug in glutamatergic strategies in the treatment of AD, which has a neuroprotective effect and relieves symptoms at the level of the remaining glutamatergic synapses. Some other formulations (cerebrolysin, nicergoline etc) can be also applied as vasoactive and neuroprotective agents.

Keywords:

Alzheimer’s disease

dementia

therapy

acetylcholinesterase inhibitors

memantine

nicergoline

Authors:

Kolykhalov I.V.

Otdel po izucheniiu bolezni Al'tsgeĭmera i assotsiirovannykh s neĭ rasstroĭstv Nauchnogo tsentra psikhicheskogo zdorov'ia RAMN, Moskva

ORCID: 0000-0002-2358-1579

Close metadata

References:

Jorm AF. Cross-national comparisons of the occurrence of Alzheimer’s and vascular dementias. Eur Arch Psychiatry Clin Neurosci. 1991;240:218-222. doi: 10.1007/bf02189530.
Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112-2117. doi: 10.1016/s0140-6736(05)67889-0.
World Alzheimer Report 2015. The Global Impact of Dementia An analysis of prevalence, incidence, cost and trends. Published by Alzheimer’s Disease International (ADI), London. 2015;82. phttp://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf.
Gavrilova SI, Kalyn JaB. Social'no-sredovye faktory i sostojanie psihicheskogo zdorov'ja pozhilogo naselenija. Vestnik Ros AMN. 2002;9:15-20. (In Russ.).
McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;146:939-944. doi: 10.1212/wnl.34.7.939.
Reisberg B, Ferris SH, Kluger A, Franssen E, Wegiel J, de Leon MJ. Mild cognitive impairment (MCI): a historical perspective. Int Psychogeriatr. 2008;20(1):18-31. doi: 10.1017/S1041610207006394.
Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976;2:1403-1404. doi: 10.1016/s0140-6736(76)91936-x.
Forette F, Boller F. Drug development in Alzheimer’s Disease. In: Gauthier S. (ed). London: Martin Dunitz. 1988;1-15. doi: 10.1017/S0714980800011041.
Delrieu J, Piau A, Caillaud C et al. Managing cognitive dysfunction through the continuum of Alzheimer's disease. Role of pharmacotherapy. CNS Drugs. 2011;25:213-226. doi: 10.2165/11539810-000000000-00000.
Rukovodstvo po geriatricheskoj psihiatrii. Pod red. Gavrilovoj SI. M.: Izdatel'stvo Pul's; 2014. (In Russ.).
Di Stefano A, Iannitelli A, Laserra S, Sozio P. Drug delivery strategies for Alzheimer’s disease treatment. Expert Opin Drug Deliv. 2011;8:581-603. doi: 10.1517/17425247.2011.561311.
Rösler M, Anand R, Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ. 1999;318:633-638. doi: 10.1136/bmj.318.7184.63.
Farlow M, Anand R, Messina J, Hartman R, Veach J. A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease. European Neurology. 2000;44(4):236-241. doi: 10.1159/000008243.
Schneider LS, Anand R, Farlow MR. Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease. Int J Geriatr Psychopharmacol. 1998;1(suppl 1):26-34. doi: 10.1159/000255578.
Feldman HH, Lane R. Rivastigmine: A placebo-controlled trial of BID and TID regimens in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2007;78:1056-1063. doi: 10.1136/jnnp.2006.099424.
Emre M, Bernabei R, Blesa R, Bullock R, Cunha L, Daniëls H, Dziadulewicz E, Förstl H, Frölich L, Gabryelewicz T, Levin O, Lindesay J, Martínez-Lage P, Monsch A, Tsolaki M, van Laar T. Drug profile: transdermal rivastigmine patch in the treatment of Alzheimer disease. CNS Neurosci Ther. 2010;16(4):246-253. doi: 10.1111/j.1755-5949.2010.00141.x.
Winblad B, Cummings J, Andreasen N et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease—rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007;22:456-467. doi: 10.1002/gps.1788.
Maelicke A. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease. Dementia and Geriatric Cognitive Disorder’s. 2000;11(suppl):11-18. doi: 10.1159/000051227.
Brodaty H, Corey-Bloom J, Potocnik FC, Truyen L, Gold M, Damaraju CR. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer’s disease. Dementia Geriatr Cogn Disord. 2005;20:120-132. doi: 10.1159/000086613.
Hing JP, Piotrovsky V, Kimko H, Brashear HR, Zhao Q. Pharmacokinetic simulation for switching from galantamine immediate-release to extended-release formulation. Curr Med Res Opin. 2005;21:483-488. doi: 10.1185/030079905X38213.
Robinson DM, Plosker GL. Galantamine extended release. CNS Drugs. 2006;20:673-681. doi: 10.2165/00023210-200620080-00006.
Hager K, Baseman AS, Nye JS, Brasher HR, Han JH, Sano M, Davis B, Richards HM. Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease. Neuropsychiatric Disease and Treatment. 2014;10:391-401. doi: 10.2147/ndt.s57909.
Rockwood K, Graham J, Fay S. Goal setting and attainment in patients with Alzheimer’s disease treated with donepezil. Journal of Neurology, Neurosurgery, and Psychiatry. 2002;73:500-507. doi: 10.1136/jnnp.73.5.500.
Mohs RC, Doody RS, Morris JC et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001;57:481-488. doi: 10.1212/WNL.57.3.481.
Doody RS, Geldmacher DS, Gordon B et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol. 2001;58:427-433. doi: 10.1001/archneur.58.3.427.
Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998;50:136. doi: 10.1212/WNL.50.1.136.
Hernandez RK, Farwell W, Cantor MD, Lawler EV. Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system. J Am Geriatr Soc. 2009;57:1997-2003. doi: 10.1111/j.1532-5415.2009.02488.x.
Lyketsos CG, Sheppard JM, Steinberg M, Tschanz JA, Norton MC, Steffens DC, Breitner JC. Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County study. Int J Geriatr Psychiatry. 2001;16:1043-1053. doi: 10.1002/gps.448.
Scarmeas N, Brandt J, Blacker D, Albert M, Hadjigeorgiou G, Dubois B, Devanand D, Honig L, Stern Y. Disruptive behavioras a predictor in Alzheimer disease. Arch Neurol. 2007;64(12):1755-1761. doi: 10.1001/archneur.64.12.1755.
Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in Alzheimer's Disease. Neurology. 2000;54:2269-2276. doi: 10.1212/WNL.54.12.2269.
Kolyhalov IV, Rassadina GA. Sravnitel'naja ocenka jeffektivnosti ingibitorov acetilholinjesterazy v lechenii povedencheskih i psihoticheskih rasstrojstv u bol'nyh demenciej v uslovijah stacionara. Psihiatrija. 2009;1:51-56. (In Russ.).
Jones RW, Bayer A, Inglis F, Barker A, Phul R. Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. Int J Geriatr Psychiatry. 2007;22(3):258-262. doi: 10.1002/gps.1752.
Schulz JB, Rainer M, Klünemann HH, Kurz A, Wolf S, Sternberg K, Tennigkeit F. Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial. J Alzheimers Dis. 2011;25(3):463-475. doi: 10.1016/j.jalz.2009.04.265.
Kolyhalov IV, Gavrilova SI, Kalyn JaB, Selezneva ND, Fedorova JaB. Sravnitel'noe klinicheskoe issledovanie bezopasnosti i perenosimosti odnorazovogo priema preparata akatinol memantin v sravnenii s dvuhrazovym priemom u pacientov s umerenno vyrazhennoj i umerenno-tjazheloj demenciej pri bolezni Al'cgejmera. Zhurnal nevropatologii i psihiatrii im. S.S. Korsakova. 2012;1:35-39. (In Russ.).
Rockenstein E, Mallory M, Mante M, Sagara Y. Effects of Cerebrolysin in Human APP Transgenic Animal Models of Alzheimer’s Disease. Neurobiol Aging. 2000;21(supl 1):168. doi: 10.1016/S0197-4580(00)82095-3.
Ruther E, Ritter R, Apecechea M, Freytag S, Windisch M. Efficacy of the Peptidergic Nootropic Drug Cerebrolysin in Patients with senile dementia of the Alzheimer Type. Pharmacopsychiatry. 1994;27:1:32-40. doi: 10.1055/s-2007-1014271.
Gavrilova SI, Kolyhalov IV, Selezneva ND, Roshhina IF, Gerasimov NP, Zharikov GA. Vlijanija cerebrolizina na jeffektivnost' i perenosimost' posledujushhej holinergicheskoj terapii u bol'nyh s bolezn'ju Al'cgejmera. Social'naja i klinicheskaja psihiatrija. 1998;8(3):58-67. (In Russ.).
Winblad B, Fioravanti M, Dolezal T, Logina I, Milanov IG, Popescu DC, Solomon A. Therapeutic use of nicergoline. Clin Drug Investig. 2008;28(9):533-552. doi: 10.2165/00044011-200828090-00001.
Fioravanti M, Flicker L. Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev. 2001;4:CD003159. doi: 10.1002/14651858.CD003159.
Winblad B, Bonura ML, Rossini BM, Battaglia A. Nicergoline in the treatment of mild-to-moderate Alzheimer's disease: a European multicentre trial. Clin Drug Invest. 2001;21(9):621-632. doi: 10.2165/00044011-200121090-00004.